Clariant teams with SICPA to launch in-product protection solution for plastic medical devices

PLASTIWARD system debuts in India at CPhI 2016


Clariant, a world leader in specialty chemicals, and SICPA SA, a trusted provider of global security solutions, have joined forces to develop and launch PLASTIWARD, a robust integrated protection for plastic pharmaceutical packaging or medical devices.

According to the World Health Organization, more than 8% of the medical devices in circulation are counterfeit, and Interpol estimates USD 75 billion in counterfeit pharmaceuticals enter the market every year. Clearly, counterfeit medical devices pose a significant liability to their manufacturers and a risk of injury, permanent disability, or even death to both patients and healthcare providers. The mission of safe access to treatments remains a challenge to medical devices and pharmaceutical companies despite investments in fighting fakes. As it is well accepted that layers of security features are necessary, the unique features of PLASTIWARD can help reinforce this approach.

The system works like this: proprietary covert taggant additives, produced by SICPA, are delivered to one of Clariant's plants where MEVOPUR brand Controlled, Consistent, Compliant materials are produced. There, the taggants are incorporated into the various polymers used in medical devices and pharmaceutical packaging, either in a concentrated masterbatch form, or as a finished polymer compound. The taggants then become part of the eventual plastic product, where they are readily detectable using SICPA's proven deployment and monitoring platform.

Once the tagged product enters the supply stream, the SICPA monitoring system is able to identify them at any point from factory to pharmacy. Products can be instantaneously authenticated at any point using a handheld detector. That data gets uploaded and aggregated on a secure inspection platform from SICPA that facilitates real-time monitoring at global, regional or local levels so that action can be taken quickly if necessary.

"PLASTIWARD offers medical-device and pharmaceutical-packaging companies a two-in-one approach," explained Steve Duckworth, Head of Global Segment Healthcare Polymer Solutions at Clariant. "It combines Clariant's track record in developing polymer compounds and masterbatches tailored to the unique requirements of clients in those sectors with SICPA's proven expertise in protecting brands and products. As part of the PLASTIWARD value proposition, our unique solution offers clients one seamless package comprising: security assessment, definition of their needs, security system design, system deployment and on-going performance monitoring."

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email